{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:02:58Z","timestamp":1789718578765,"version":"4.0.1"},"reference-count":68,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CTEP protocol 10191"],"award-info":[{"award-number":["CTEP protocol 10191"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1 CA186709"],"award-info":[{"award-number":["UM1 CA186709"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Biomarker supplement to UM1 CA186709"],"award-info":[{"award-number":["Biomarker supplement to UM1 CA186709"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["CDMRP PCRP Translational Science Award PC190196 \u2013"],"award-info":[{"award-number":["CDMRP PCRP Translational Science Award PC190196 \u2013"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["Grant 12907103"],"award-info":[{"award-number":["Grant 12907103"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["Supplied berzosertib via the NCI Pharmaceutical Management Branch"],"award-info":[{"award-number":["Supplied berzosertib via the NCI Pharmaceutical Management Branch"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Inhibitors of the ataxia-telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anticancer activity with platinum compounds in preclinical models. We therefore conducted a phase II study of the ATR inhibitor berzosertib + carboplatin versus docetaxel + carboplatin in metastatic castration-resistant prostate cancer (mCRPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients previously treated with at least one androgen receptor pathway inhibitor and taxane underwent mandatory biopsy and were randomized 1:1 to receive arm A (docetaxel 60 mg\/m2 + carboplatin AUC4 day 1 or carboplatin AUC5 if not a docetaxel candidate) or arm B (berzosertib 90 mg\/m2 days 2 and 9 + carboplatin AUC5 day 1) every 21 days. The primary endpoint was overall response rate (ORR; \u226550% PSA decline or radiographic response).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 73 randomized patients, 65 received protocol treatment: 34 on arm A (26 docetaxel + carboplatin and 8 carboplatin alone) and 31 on arm B. Thirteen patients (38%) in arm A and 20 (65%) in arm B had \u2265 grade 3 treatment-related adverse events (TrAE). ORR was 15% in arm A [5\/34; 5\/26 (19%) with docetaxel + carboplatin] and 0% in arm B (0\/31). At interim analysis, after 65 of the planned 130 patients were treated, enrollment was halted due to futility. Homologous recombination repair (HRR) deficiency status from tissue and blood did not correlate with clinical outcomes, but ATM deficiency or high levels of phospho-Kr\u00fcppel-associated box (KRAB) domain\u2013associated protein 1 (pKAP1) detected in tissue were associated with clinical benefit across both arms of the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Berzosertib + carboplatin demonstrated lower ORR and more frequent \u2265 grade 3 TrAEs compared with docetaxel + carboplatin in this heavily pretreated, biomarker-unselected population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The combination of the ATR inhibitor berzosertib with carboplatin demonstrated a lower ORR compared with docetaxel with carboplatin in a heavily pretreated biomarker-unselected mCRPC population. Assays for HRR deficiency showed limited predictive capability, but a combined tissue biomarker of ATM deficiency and elevated pKAP1 (indicating elevated replication stress) was associated with benefit in both study arms and warrants investigation for benefit from carboplatin-based therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0488","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:52:32Z","timestamp":1787586752000},"page":"2206-2219","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-6631","authenticated-orcid":false,"given":"Atish D.","family":"Choudhury","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9561-1439","authenticated-orcid":false,"given":"Caiwei","family":"Zhong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-8000","authenticated-orcid":false,"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8929-3070","authenticated-orcid":false,"given":"Bose S.","family":"Kochupurakkal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-4871","authenticated-orcid":false,"given":"Peter I-Fan","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v6m3209","id-type":"ROR","asserted-by":"publisher"}],"name":"Frederick National Laboratory for Cancer Research 3 Molecular Characterization Laboratory, , Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4249-0311","authenticated-orcid":false,"given":"Irbaz Bin","family":"Riaz","sequence":"additional","affiliation":[{"name":"4Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-6335","authenticated-orcid":false,"given":"Ruolin","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Broad Institute of MIT and Harvard 5 , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-218X","authenticated-orcid":false,"given":"David D.","family":"Yang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Broad Institute of MIT and Harvard 5 , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-7073","authenticated-orcid":false,"given":"Edmund","family":"Folefac","sequence":"additional","affiliation":[{"name":"6The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-3595","authenticated-orcid":false,"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01an3r305","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pittsburgh 7 , Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7300-7452","authenticated-orcid":false,"given":"Mamta","family":"Parikh","sequence":"additional","affiliation":[{"name":"8UC Davis Comprehensive Cancer Center, Sacramento, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-3281","authenticated-orcid":false,"given":"David J.","family":"Einstein","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04drvxt59","id-type":"ROR","asserted-by":"publisher"}],"name":"Beth Israel Deaconess Medical Center 9 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-867X","authenticated-orcid":false,"given":"Elizabeth R.","family":"Kessler","sequence":"additional","affiliation":[{"name":"10University of Colorado Hospital Cancer Center, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0078-3773","authenticated-orcid":false,"given":"Tina","family":"Mayer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0060x3y55","id-type":"ROR","asserted-by":"publisher"}],"name":"Rutgers Cancer Institute of New Jersey 11 , New Brunswick, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qkmtm61","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California San Diego Moores Cancer Center 12 , La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5360-4105","authenticated-orcid":false,"given":"Amanda","family":"Pace","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7343","authenticated-orcid":false,"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-5912","authenticated-orcid":false,"given":"Li","family":"Chen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v6m3209","id-type":"ROR","asserted-by":"publisher"}],"name":"Frederick National Laboratory for Cancer Research 3 Molecular Characterization Laboratory, , Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-2485","authenticated-orcid":false,"given":"Viktor A.","family":"Adalsteinsson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Broad Institute of MIT and Harvard 5 , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4056-9004","authenticated-orcid":false,"given":"Charles A.","family":"Kunos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01dhvva97","id-type":"ROR","asserted-by":"publisher"}],"name":"Markey Cancer Center 13 , University of Kentucky, Lexington, Kentucky."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2139-5653","authenticated-orcid":false,"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 14 Cancer Therapy Evaluation Program, , Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-2926","authenticated-orcid":false,"given":"Biswajit","family":"Das","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v6m3209","id-type":"ROR","asserted-by":"publisher"}],"name":"Frederick National Laboratory for Cancer Research 3 Molecular Characterization Laboratory, , Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6294","authenticated-orcid":false,"given":"Alan","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3384-0300","authenticated-orcid":false,"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 , Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091803215151800_bib1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"key":"2026091803215151800_bib2","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026091803215151800_bib3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"2026091803215151800_bib4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091803215151800_bib5","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091803215151800_bib6","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"2026091803215151800_bib7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/s0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"2026091803215151800_bib8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091803215151800_bib9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026091803215151800_bib10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"key":"2026091803215151800_bib11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.annonc.2025.05.534","article-title":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","volume":"36","author":"Olmos","year":"2025","journal-title":"Ann Oncol"},{"key":"2026091803215151800_bib12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur Urol"},{"key":"2026091803215151800_bib13","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"Supplement 5","key":"2026091803215151800_bib14","doi-asserted-by":"publisher","first-page":"v327","DOI":"10.1093\/annonc\/mdz248.003","article-title":"846PD - Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses","volume":"30","author":"Abida","year":"2019","journal-title":"Ann Oncol"},{"key":"2026091803215151800_bib15","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026091803215151800_bib16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/genes7080051","article-title":"Targeting DNA replication stress for cancer therapy","volume":"7","author":"Zhang","year":"2016","journal-title":"Genes (Basel)"},{"key":"2026091803215151800_bib17","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"key":"2026091803215151800_bib18","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng","year":"2016","journal-title":"Eur Urol"},{"key":"2026091803215151800_bib19","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1002\/cncr.30808","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","volume":"123","author":"Pomerantz","year":"2017","journal-title":"Cancer"},{"key":"2026091803215151800_bib20","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026091803215151800_bib21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.molcel.2012.02.015","article-title":"BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair","volume":"46","author":"Bunting","year":"2012","journal-title":"Mol Cell"},{"key":"2026091803215151800_bib22","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep"},{"key":"2026091803215151800_bib23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","article-title":"A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","volume":"75","author":"Ceccaldi","year":"2015","journal-title":"Cancer Res"},{"key":"2026091803215151800_bib24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev"},{"key":"2026091803215151800_bib25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cncr.23195","article-title":"A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"2026091803215151800_bib26","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026091803215151800_bib27","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026091803215151800_bib28","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/jco.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026091803215151800_bib29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/annonc\/mdw156","article-title":"Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review","volume":"27","author":"Hager","year":"2016","journal-title":"Ann Oncol"},{"issue":"13_Supplement","key":"2026091803215151800_bib30","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/1538-7445.Am2017-2796","article-title":"Abstract 2796: development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity","volume":"77","author":"Kochupurakkal","year":"2017","journal-title":"Cancer Res"},{"key":"2026091803215151800_bib31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.Ccr-25-0571","article-title":"A phase Ib study of sapacitabine and olaparib in patients with BRCA1\/2-mutated metastatic breast cancer","volume":"32","author":"Lynce","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026091803215151800_bib32","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1038\/s41467-021-25904-w","article-title":"A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer","volume":"12","author":"Konstantinopoulos","year":"2021","journal-title":"Nat Commun"},{"key":"2026091803215151800_bib33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.Cir-22-0306","article-title":"Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2026091803215151800_bib34","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"2026091803215151800_bib35","doi-asserted-by":"publisher","first-page":"gkaf313","DOI":"10.1093\/nar\/gkaf313","article-title":"DirectHRD enables sensitive scar-based classification of homologous recombination deficiency","volume":"53","author":"Liu","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2026091803215151800_bib36","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1200\/jco.23.00402","article-title":"Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI Protocol 10250)","volume":"41","author":"Ingham","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026091803215151800_bib37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026091803215151800_bib38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol Cancer Res"},{"key":"2026091803215151800_bib39","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53-or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"issue":"13_Supplement","key":"2026091803215151800_bib40","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1158\/1538-7445.Am2018-1620","article-title":"Abstract 1620: ATR inhibition for the treatment of ATM-deficient gastric cancer","volume":"78","author":"Cai","year":"2018","journal-title":"Cancer Res"},{"key":"2026091803215151800_bib41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/1541-7786.MCR-11-0134","article-title":"The ATM substrate KAP1 controls DNA repair in heterochromatin: regulation by HP1 proteins and serine 473\/824 phosphorylation","volume":"10","author":"White","year":"2012","journal-title":"Mol Cancer Res"},{"key":"2026091803215151800_bib42","doi-asserted-by":"publisher","first-page":"18937","DOI":"10.1074\/jbc.M111.313262","article-title":"Roles of Kruppel-associated box (KRAB)-associated co-repressor KAP1 Ser-473 phosphorylation in DNA damage response","volume":"287","author":"Hu","year":"2012","journal-title":"J Biol Chem"},{"key":"2026091803215151800_bib43","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1158\/1078-0432.Ccr-24-3936","article-title":"Reclassification of ATM missense variants of uncertain significance by integrating results from systematic functional assays into an ACMG points-based framework","volume":"31","author":"Hanenberg","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026091803215151800_bib44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026091803215151800_bib45","doi-asserted-by":"publisher","first-page":"9467","DOI":"10.1093\/nar\/gkz694","article-title":"DNA-PKcs promotes chromatin decondensation to facilitate initiation of the DNA damage response","volume":"47","author":"Lu","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"7_Supplement","key":"2026091803215151800_bib46","doi-asserted-by":"publisher","first-page":"CT222","DOI":"10.1158\/1538-7445.am2024-ct222","article-title":"Abstract CT222: efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)","volume":"84","author":"Aggarwal","year":"2024","journal-title":"Cancer Res"},{"key":"2026091803215151800_bib47","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/2159-8290.Cd-24-1500","article-title":"Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects","volume":"15","author":"Yap","year":"2025","journal-title":"Cancer Discov"},{"key":"2026091803215151800_bib48","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"2026091803215151800_bib49","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Mol Cell"},{"key":"2026091803215151800_bib50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/pmic.201500172","article-title":"ATR inhibition rewires cellular signaling networks induced by replication stress","volume":"16","author":"Wagner","year":"2016","journal-title":"Proteomics"},{"key":"2026091803215151800_bib51","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1038\/s41388-025-03343-x","article-title":"Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer","volume":"44","author":"Hofstad","year":"2025","journal-title":"Oncogene"},{"key":"2026091803215151800_bib52","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1535-7163.Mct-22-0685","article-title":"Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors","volume":"22","author":"Turchick","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026091803215151800_bib53","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaoncol.2021.3441","article-title":"Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Pal","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026091803215151800_bib54","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1158\/2767-9764.Crc-25-0305","article-title":"The ATR inhibitor elimusertib in combination with cisplatin in patients with advanced solid tumors: a California Cancer Consortium phase I trial (NCI 10404)","volume":"5","author":"Parikh","year":"2025","journal-title":"Cancer Res Commun"},{"key":"2026091803215151800_bib55","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026091803215151800_bib56","doi-asserted-by":"publisher","first-page":"e2500055","DOI":"10.1200\/po-25-00055","article-title":"Safety and tolerability of berzosertib, an ataxia-telangiectasia-related inhibitor, and veliparib, an oral poly (ADP-ribose) polymerase inhibitor, in combination with cisplatin in patients with refractory solid tumors","volume":"9","author":"O\u2019Sullivan Coyne","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026091803215151800_bib57","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.eururo.2020.10.001","article-title":"Taxane-induced attenuation of the CXCR2\/BCL-2 axis sensitizes prostate cancer to platinum-based treatment","volume":"79","author":"Ruiz de Porras","year":"2021","journal-title":"Eur Urol"},{"key":"2026091803215151800_bib58","doi-asserted-by":"publisher","first-page":"17562872241229876","DOI":"10.1177\/17562872241229876","article-title":"Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial","volume":"16","author":"Coquan","year":"2024","journal-title":"Ther Adv Urol"},{"key":"2026091803215151800_bib59","doi-asserted-by":"publisher","first-page":"e2500310","DOI":"10.1200\/po-25-00310","article-title":"Activity of platinum monotherapy in patients with metastatic castration-resistant prostate cancer and DNA damage repair gene alterations","volume":"9","author":"Aldea","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"16_suppl","key":"2026091803215151800_bib60","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1200\/JCO.2025.43.16_suppl.5058","article-title":"Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V)\u2014a circulating tumor DNA (ctDNA)\u2013directed phase II study of carboplatin in patients (Pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Rose","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"2026091803215151800_bib61","doi-asserted-by":"publisher","first-page":"TPS291","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS291","article-title":"Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: phase II single-arm trial (CiPHeR)","volume":"43","author":"Jain","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026091803215151800_bib62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eururo.2018.09.040","article-title":"Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects","volume":"76","author":"Isaacsson Velho","year":"2019","journal-title":"Eur Urol"},{"key":"2026091803215151800_bib63","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41591-025-03704-9","article-title":"Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","volume":"31","author":"Kwan","year":"2025","journal-title":"Nat Med"},{"key":"2026091803215151800_bib64","doi-asserted-by":"publisher","first-page":"e152789","DOI":"10.1172\/jci.insight.152789","article-title":"Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer","volume":"6","author":"De Sarkar","year":"2021","journal-title":"JCI Insight"},{"key":"2026091803215151800_bib65","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1158\/1078-0432.Ccr-19-2135","article-title":"Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1\/2 mutations","volume":"26","author":"Sztupinszki","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026091803215151800_bib66","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"6_suppl","key":"2026091803215151800_bib67","doi-asserted-by":"crossref","first-page":"TPS252","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS252","article-title":"A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer","volume":"38","author":"Choudhury","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2026091803215151800_bib68","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2021.39.15_suppl.5034","article-title":"A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer","volume":"39","author":"Choudhury","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0488\/3824023\/crc-26-0488.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2206\/3830366\/crc-26-0488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2206\/3830366\/crc-26-0488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:21:58Z","timestamp":1789716118000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/9\/2206\/788359\/A-Phase-II-Study-of-Berzosertib-in-Combination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0488","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33923280","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923298","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923277","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923274","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923286","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923283","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923295","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923292","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923271","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923307","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923304","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923301","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33923289","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8723409","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}